del(13q) in non-Hodgkin's lymphoma

Antonio Cuneo

Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy (AC)

Published in Atlas Database: November 1999
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/del13qNHLID2070.html
DOI: 10.4267/2042/37559

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 1999 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Note: the chromosome 13q deletion is a relatively common finding in chronic myeloproliferative disorders and lymphoid neoplasias, including B-cell chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Whereas the commonly deleted region comprise a 100-kb gene-rich segment at the 13q14 chromosome band in CLL, the commonly deleted segment in NHL was not characterized in detail.

Clinics and pathology

Disease
B-NHL

Phenotype/cell stem origin
Peripheral B-cells at different stages of differentiation.
Pre-germinatal centre: small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL).
Post-germinatal centre: marginal zone B-cell lymphoma (MZBCL) follicle centre cell lymphoma (FCCL), diffuse large cell lymphoma (DLCL).

Epidemiology
Incidence.
SLL: 5-10% of all NHL diagnosed by surgical biopsy.
MCL: 5-10% of all NHL in western countries.
MZBCL: 0-15% of NHL, including the extra-nodal form the nodal and the splenic form.
FCCL: 30-40% of NHL.
DLCL: 30-40% of NHL.

Clinics
SLL: low-grade histology, usually running an indolent course; survival largely dependent on clinical stage at presentation.
MCL: intermediate-grade histology, poor response to therapy, median survival 3-4 years.
MZBCL: low-grade histology, indolent disease, median survival >5 years.
FCCL: low-grade histology, indolent disease, median survival >5 years.
DLCL: high grade histology, aggressive disease, survival influenced by age, stage at presentation, performance status.

Prognosis
The significance of 13q- is uncertain because of heterogeneity of patients population and histology; a low CR rate was described but it is not clear whether this depends on its close association with MCL.

Cytogenetics

Additional anomalies
With the notable exception of SLL/CLL the 13q deletion is not found as an isolated change in NHL;
it was reported as a stemline-associated anomaly in most cases having complex karyotypes, suggesting that it may represent a relatively early event in the cytogenetic history of NHL; the association with other anomalies reflects the incidence of the 13q-chromosome in distinct histologic subsets: thus it was frequently found in karyotypes presenting the t(11;14)(q13;q32); many patients with the inv(14)(q11q32), associated with T-cell lymphoid neoplasias, were found to carry a 13q- chromosome.

### Genes involved and proteins

**Note**
Involved loci: the few characterized cases showed a deletion of the D13S319 marker, located between the Rb locus and the D13S25 marker; FISH studies were performed using probes targeting the Rb locus or the loci comprised between Rb and the D13S25 marker.

### References


This article should be referenced as such: